There is a review of the evidence on current and future therapies for IgA Nephropathy. The review appears to cover various aspects of the disease, including pathogenesis, diagnosis, prognosis, and treatment options, such as new targeted therapies and the use of certain inhibitors. However, some reports seem to be focused on related or broader topics, including pain management in chronic kidney disease and general health and welfare issues, making it unclear how directly they relate to IgA Nephropathy therapies.